Início
Mercados
Gráficos e ideias
Algo
Notícias
Store
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
CRDL
#5403
Cardiol Therapeutics Inc. Class A Common Shares
1.0
2
-0.97%
Setor:
Base:
Moeda do lucro:
Faixa diária
Faixa anual
Mudança diária
-0.97%
Mudança mensal
+4.08%
Mudança em 6 meses
-8.93%
Mudança anual
-13.56%
Fechamento anterior
1.0
3
Open
1.0
2
Bid
Ask
Low
1.0
2
High
1.0
2
Volume
3
Mercados
Ações
Cuidados de saúde
CRDL
Open full chart
Financials
Overview
Relatórios
Statistics
Dividends
Quarterly
Annual
Value
2022
2023
2024
TTM
Key stats
Total common shares outstanding
64.04 M
65.35 M
82.61 M
—
Valuation ratios
Enterprise value
34.59 M
57.51 M
105.74 M
—
Price to earnings ratio
—
—
—
—
Price to sales ratio
—
—
—
—
Price to cash flow ratio
—
—
—
—
Price to book ratio
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
Profitability ratios
Return on assets %
—
—
—
—
Return on equity %
—
—
—
—
Return on invested capital %
—
—
—
—
Gross margin %
—
—
—
—
Operating margin %
—
—
—
—
EBITDA margin %
—
—
—
—
Net margin %
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
Current ratio
—
—
—
—
Inventory turnover
—
—
—
—
Asset turnover
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
EBIT per share
—
—
—
—
EBITDA per share
—
—
—
—
Total debt per share
—
—
—
—
Cash per share
—
—
—
—
Net current asset value per share
—
—
—
—
Tangible book value per share
—
—
—
—
Working capital per share
—
—
—
—
Book value per share
—
—
—
—
Notícias
Cardiol Therapeutics publica resultados do estudo de fase II sobre miocardite
Cardiol Therapeutics publishes phase II myocarditis study results
Cardiol Therapeutics registra acordo de subscrição e contrato de garantia
Cardiol Therapeutics files underwriting agreement and warrant indenture
Cardiol Therapeutics anuncia colocação privada de US$ 13,5 milhões
Cardiol Therapeutics announces $13.5 million private placement
Cardiol Therapeutics anuncia financiamento de US$ 13,5 milhões
Cardiol Therapeutics announces $13.5 million bought deal financing
Cardiol Therapeutics atinge 50% de recrutamento em ensaio de pericardite recorrente
Cardiol Therapeutics reaches 50% enrollment in recurrent pericarditis trial
H.C. Wainwright mantém recomendação de compra para Cardiol Therapeutics com preço-alvo de US$ 9
H.C. Wainwright reaffirms Buy rating on Cardiol Therapeutics stock at $9 target